Am J Gastroenterol

Subcutaneous infliximab shows promise for perianal Crohn’s disease in multicenter study

September 9, 2025

Study details: This multicentre retrospective cohort study evaluated SC infliximab (IFX) in 183 patients with perianal Crohn’s disease (pCD) across 24 centers. Patients were stratified into two groups: those with active pCD initiating SC infliximab (group 1; n=66) and those with inactive pCD switching from IV to SC infliximab (group 2; n=117). Primary endpoints were clinical remission at 6 months (group 1) and relapse rates (group 2)

Results: At 6 months, clinical remission was achieved in 44.6% of patients with active pCD, with a clinical response rate of 87.7%. Remission with seton removal occurred in 35.5%. High BMI was inversely associated with remission (odds ratio [OR], 0.88, 95% confidence interval [CI], 0.77–0.99). Among patients switched from IV to SC infliximab, relapse-free survival was 94.3% at 6 months and 87.9% at 12 months. Adverse events related to SC injection were infrequent (8.3%).

Clinical impact: SC IFX demonstrated strong efficacy and safety for both inducing remission in active pCD and maintaining remission in previously stable cases. These findings support SC IFX as a viable alternative to IV therapy, offering convenience without compromising outcomes.

Source:

André M, et al; GETAID BioLap-Rem study group.. (2025, August 28). Am J Gastroenterol. Sub-cutaneous infliximab for perianal Crohn's disease: the BioLap-Rem multicentre study from the GETAID. https://pubmed.ncbi.nlm.nih.gov/40874971/